4-allyl-2-methylbenzonitrile | 1233500-55-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-allyl-2-methylbenzonitrile
• 英文别名: 2-Methyl-4-prop-2-enylbenzonitrile
• CAS: 1233500-55-4
• 化学式: C₁₁H₁₁N
• 分子量: 157.215
• InChiKey: ADHAQBKSZOBIPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] PYRAZOLE DERIVATIVES AS S1P1 AGONISTS<br/>[FR] DÉRIVÉS DU PYRAZOLE EN TANT QU'AGONISTES S1P1
  申请人：ALMIRALL SA

  公开号：WO2011144338A1

  公开（公告）日：2011-11-24

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by sphingosine-1-phosphate receptors (S1P1) agonists.

  本发明涉及式(I)的化合物，制备此类化合物的方法以及它们在治疗可通过鞘氨醇-1-磷酸受体（S1P1）激动剂改善的病理状况或疾病中的用途。
• New pyrazole derivatives
  申请人：Almirall, S.A.

  公开号：EP2390252A1

  公开（公告）日：2011-11-30

  The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by sphingosine-1-phosphate receptors (S1P1) agonists.

  本发明涉及式(I)的化合物，其制备过程，以及它们在治疗可通过sphingosine-1-phosphate受体（S1P1）激动剂改善的病理状况或疾病中的用途。
• 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE
  申请人：Giulio Matassa Victor

  公开号：US20110311485A1

  公开（公告）日：2011-12-22

  The present disclosure relates to 1, 2, 4 oxadiazole derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the S1P1 receptors.

  本公开涉及公式（I）的1,2,4-噁二唑衍生物，以及包含它们的药物组合物，以及它们作为S1P1受体激动剂在治疗中的使用。
• Inhibitors of the Renal Outer Medullary Potassium Channel
  申请人：Pasternak Alexander

  公开号：US20130217680A1

  公开（公告）日：2013-08-22

  This invention relates to compounds having structural Formula (I); and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir 1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

  本发明涉及具有结构式（I）的化合物及其药学上可接受的盐，它们是肾外髓质钾（ROMK）通道（Kir 1.1）的抑制剂。公式I的化合物可用作利尿剂和钠利尿剂，因此可用于治疗和预防由过度盐和水潴留引起的疾病，包括高血压和慢性和急性心力衰竭等心血管疾病。
• 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE
  申请人：Almirall S.A.

  公开号：EP2370431A1

  公开（公告）日：2011-10-05